Breaking News Instant updates and real-time market news.

KDMN

Kadmon

$6.04

-0.07 (-1.15%)

14:26
11/20/16
11/20
14:26
11/20/16
14:26

Kadmon reports new data on tesevatinib in kidney cyst patients

Kadmon announced additional data from its ongoing Phase 2a clinical study demonstrating the safety of tesevatinib for the treatment of autosomal dominant polycystic kidney disease. The data will be presented at the American Society of Nephrology Kidney Week. "Recent findings from Kadmon's ongoing Phase 2a study in patients with ADPKD have demonstrated that tesevatinib is well tolerated and have also identified tesevatinib 50 mg once daily as the optimal dose to treat ADPKD. New data reported in the poster indicate that tesevatinib is a new member of a group of drugs known as MATE 1/2-K transporter inhibitors, such as cimetidine, which mildly increase levels of serum creatinine. Normally, an increase in serum creatinine can be used to indicate kidney damage, but in the case of MATE 1/2-K inhibitors, these serum creatinine increases occur without clinically meaningful alterations in renal function. Specifically, new data demonstrated that serum creatinine levels in tesevatinib patients increased by 10%-14% during the first 28 days of treatment and reversed upon treatment discontinuation. Importantly, levels of cystatin C, another measure of renal function, were relatively unchanged during the same period. In vitro studies demonstrated that tesevatinib potently inhibits MATE1/2-K transporters at tesevatinib concentrations achieved with the 50 mg QD dose. Therefore, MATE inhibition by tesevatinib may explain mild serum creatinine increases associated with tesevatinib treatment," the company reported. "Kadmon has had discussions with the FDA to develop innovative methods to demonstrate drug safety and efficacy in PKD, a major unmet medical need. These discussions will have important implications for clinical trial designs for tesevatinib as well as other therapies in development for renal diseases, especially MATE inhibitors," noted CMO John Ryan.

  • 29

    Nov

KDMN Kadmon
$6.04

-0.07 (-1.15%)

08/22/16
SBSH
08/22/16
INITIATION
Target $12
SBSH
Neutral
Kadmon initiated with a Neutral at Citi
Citi analyst Robyn Karnauskas initiated Kadmon with a Neutral and $12 price target saying most of its programs are risky with limited clinical data, and the ongoing trials are small proof of concept trials which could limit the upside.
08/22/16
HCWC
08/22/16
INITIATION
Target $25
HCWC
Buy
Kadmon initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein initiated Kadmon with a Buy and $25 price target.
08/22/16
08/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AK Steel (AKS) initiated with a Neutral at Citi and a Buy at Rosenblatt. 2. U.S. Steel (X) and Steel Dynamics (STLD) were initiated with a Buy at Citi while the firm initiated Nucor (NUE) and Commercial Metals (CMC) with a Neutral. 3. Pinnacle Entertainment (PNK) initiated with a Buy at BofA/Merrill. 4. Ferrellgas Partners LP (FGP) initiated with a Neutral at Piper Jaffray. 5. Kadmon (KDMN) initiated with an Outperform at JMP Securities, with a Neutral at Citi, and with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/15/16
JMPS
09/15/16
NO CHANGE
JMPS
Kadmon has positive read through from Allergan deal, says JMP Securities
JMP Securities analyst Michael King says that Allergan's (AGN) acquisition of Vitae Pharmaceuticals (VTAE) bodes well for Kadmon's (KDMN) ROCK inhibitor KD025 for patients with psoriasis. The analyst says that the main driver for the Vitae deal was its oral RORyt inhibitor VTP-43742 which could become a psoriasis treatment. There are "mechanistic similarities" between Vitae's drug and Kadmon's psoriasis drug candidate KD025, King wrote. He reiterates a $16 price target and Outperform rating on Kadmon.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.